In this episode of Cardiology Digest, we dive into top journals like JAMA Cardiology to bring you three of the most compelling recent research papers from the field of cardiology.

STUDY #1: First, see how the new Boston Scientific cryoballoon measures up against Medtronic's product. Did the newcomer outshine the veteran, or does it come with hidden risks? Discover the head-to-head results and what they mean for the future of atrial fibrillation cryoablation.

Reichlin, T, Kueffer, T, Knecht, S et al. 2024. PolarX vs Arctic Front for cryoballoon ablation of paroxysmal AF: The randomized COMPARE CRYO study. JACC Clin Electrophysiol. In Press, Corrected Proof. (https://doi.org/10.1016/j.jacep.2024.03.021)

STUDY #2: Next, we explore the intersection of aging, aortic stenosis, and osteosarcopenia in elderly patients undergoing transcatheter aortic valve replacement. This study highlights a radiographic method that reveals a high-risk subpopulation within this demographic. See how this insight can shape our approach to transcatheter aortic valve replacement, and what it means for patient care strategies.

Solla-Suarez, P, Arif, S, Ahmad, F, et al. 2024. Osteosarcopenia and mortality in older adults undergoing transcatheter aortic valve replacement. JAMA Cardiol. 7: 611-618. (https://doi.org/10.1001/jamacardio.2024.0911)

O'Gara, P, Guduguntla, V, Bonow, R, et al. 2024, Osteosarcopenia and mortality after transcatheter aortic valve replacement. JAMA Cardiol. 7: 618-619. (https://doi.org/10.1001/jamacardio.2024.1018)

STUDY #3: Finally, we turn our attention to the pressing issue of hypertensive disorders in pregnancy. Discover why close postpartum monitoring is critical and what the latest research suggests about the persistence of hypertension in new mothers. Could longer follow-ups hold the key to better postpartum care?

Hauspurg, A, Venkatakrishnan, K, Collins, L, et al. 2024. Postpartum ambulatory blood pressure patterns following new-onset hypertensive disorders of pregnancy. JAMA Cardiol. Published online (https://doi.org/10.1001/jamacardio.2024.1389)

Join us to unravel these important studies and their implications for your practice and patients. Ready to stay ahead in the rapidly evolving world of cardiology? Hit play and let's get started!

Learn more with Medmastery's courses:

Holter Monitoring Essentials (2 CME)

Get a Basic or Pro account, or, get a Trial account.

Show notes:

Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

Ready to dig into the latest cardiology research? In less than 15 minutes, we'll give you the low-down on three new studies that’ll help you in clinical practice.

STUDY #1: First, we explore safety outcomes for carotid artery stenting and see how this could impact your clinical discussions and decision-making. And if you practice in the U.S., now that Medicare and Medicaid cover this procedure for a broader range of patients, this info will prove to be especially important.

Uchida, K, Sakakibara, F, Sakai, N, et al. 2024. Real-world outcomes of carotid artery stenting in symptomatic and asymptomatic patients with carotid artery stenosis. JACC Cardiovasc Interv. 9: 1160-1162. (https://doi.org/10.1016/j.jcin.2024.03.014)

STUDY #2: Next, we tackle a common cardiology conundrum: how should we handle significant coronary artery disease lesions discovered incidentally in patients with severe aortic stenosis who are undergoing transcatheter aortic valve replacement? Is it better to treat these lesions beforehand, or is there a better strategy? We'll probe the debate, highlighting the potential implications of this new data.

Colaiori, I, Paolucci, L, Mangiacapra, F, et al. 2024. Natural history of coronary atherosclerosis in patients with aortic stenosis undergoing transcatheter aortic valve replacement: The role of quantitative flow ratio. Circ Cardiovasc Interv. 0: e013705. (https://doi.org/10.1161/CIRCINTERVENTIONS.123.013705)

STUDY #3: Lastly, we sip our way through the nuances of coffee consumption and its impact on blood pressure and cardiac arrhythmias. A new study lets us know whether our patients' daily caffeine fix can be left off the list of cardiac concerns.

Trevano, F, Vela-Bernal, S, Facchetti, R, et al. 2024. Habitual coffee consumption and office, home, and ambulatory blood pressure: Results of a 10-year prospective study. J Hypertens. 6: 1094-1100. (https://doi.org/10.1097/HJH.0000000000003709)

Join us to break down these studies, and elevate your cardiology knowledge!

Learn more with these courses:

Coronary Angiography Essentials (3 CME)

Coronary Angiography Essentials Workshop (1 CME)

Get a Basic or Pro account, or, get a Trial account.

Show notes:

Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

In less than 15 minutes, Medmastery’s Cardiology Digest will give you the low-down on some of the most compelling studies in cardiology that clinicians with an interest in cardiovascular health need to know about.

STUDY #1: We kick things off by exploring exactly where the CHA2DS2-VASc score fits into anticoagulation decisions in patients with silent atrial fibrillation. Building on the main findings from the ARTESiA and NOAH-AFNET 6 trials, this study sparks a thought-provoking discussion on the future of risk stratification. Tune in to hear insights that could shape your clinical practice.

Lopes, RD, Granger, CB, Wojdyla, DM, et al. 2024. Apixaban versus aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: Insights from ARTESiA. J Am Coll Cardiol. In Press, Journal Pre-proof. (https://doi.org/10.1016/j.jacc.2024.05.002)

STUDY #2: Next, we break down misconceptions surrounding race and treatment efficacy in heart failure with reduced ejection fraction. This study shines a light on the impacts of renin-angiotensin system inhibition across different racial groups. See how these findings challenge the outdated genetic constructs of race, and what they mean for your approach to patient care.

Shen, L, Lee, MM, Jhund, PS, et al. 2024. Revisiting race and the benefit of RAS blockade in heart failure: A meta-analysis of randomized clinical trials. JAMA. 24: 2094–2104. (https://doi.org/10.1001/jama.2024.6774)

STUDY #3: Finally, we turn our focus to the V142I transthyretin gene variant, to evaluate its impacts on cardiovascular health within the U.S. Black population. This research not only highlights the need for targeted genetic screening but also raises important questions about the accessibility of costly treatments for transthyretin amyloidosis.

Selvaraj, S, Claggett, B, Shah, SH, et al. 2024. Cardiovascular burden of the V142I transthyretin variant. JAMA. 21: 1824–1833. (https://doi.org/10.1001/jama.2024.4467)

Maurer, MS, Miller, EJ, Ruberg, FL, et al. 2024. Addressing health disparities—The case for variant transthyretin cardiac amyloidosis grows stronger. JAMA. 21: 1809–1811. (https://doi.org/10.1001/jama.2024.2868)

Yancy, CW. 2024. Heart failure in African American individuals, Version 2.0. JJAMA. 21: 1807–1808. (https://doi.org/10.1001/jama.2024.5217)

Don't miss out on this rich discussion that promises to enhance your understanding and expertise!

Learn more with these courses:

Medical Treatment of Heart Failure (2 CME)

Atrial Fibrillation Management Essentials (1 CME)

Get a Basic or Pro account, or, get a Trial account.

Show notes:

Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.